Vericel has reported a notable 20% increase in revenue for the latest quarter, signaling strong performance in the biotech sector.
This growth has attracted the attention of investors, particularly a prominent biotech investor who has added $63 million to their existing stake in the company.
The recent developments suggest a growing confidence in Vericel's products and overall market position.